The CFO change itself is now formalized, not an earnings surprise. The agreement confirms that Michael Grasher will serve as CFO, but the appointment was publicly announced on August 31, 2026, so the identity and role were already visible to investors by the filing date. 〔0〕
The contract gives Grasher meaningful downside protection if Teladoc terminates him without cause. Outside a change of control, he receives 12 months of base-salary continuation, COBRA coverage for up to 12 months, certain bonus payments, and accelerated service-based equity vesting scheduled within the following year. 〔1〕
| Key term | Disclosed provision |
|---|---|
| Severance outside change of control | 12 months of base salary (Section 2(a)) |
| Health coverage outside change of control | Up to 12 months of COBRA premiums (Section 2(a)(v)) |
| Severance after change of control | 18 months of base salary (Section 2(b)) |
| Additional change-of-control payment | 100% of target bonus (Section 2(b)) |
| Equity after change of control | Immediate time-based vesting; performance awards remain eligible (Section 2(b)) |
| Restrictive covenants | 12-month non-solicitation and non-competition period (Section 4) |
Change-of-control protection is materially richer, but its dollar cost cannot be assessed from this filing. If Grasher is terminated without cause or resigns for good reason within 12 months after a change of control, the salary continuation extends to 18 months, he receives an additional 100% of target bonus, and all unvested equity awards vest as to time. 〔2〕 〔3〕
Net read: neutral because this is a personnel and compensation disclosure, not a change to Teladoc’s business outlook. The terms are important for future transaction or retention economics, but the filing gives no salary, target-bonus, equity-grant, performance, guidance, or capital-allocation figures against which to claim a beat or miss. The appointment direction was partly known; the severance mechanics are the new detail.
Read the original 8-K on SEC EDGAR ↗